{"id":"kl-a167","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"KL-A167 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing its interaction with PD-1 and B7-1 receptors on T cells. This blockade reverses T cell exhaustion and restores anti-tumor immunity, allowing the immune system to recognize and eliminate cancer cells more effectively.","oneSentence":"KL-A167 is a humanized monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:49:09.010Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT07371208","phase":"PHASE2","title":"Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2025-12-24","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT07296809","phase":"PHASE2","title":"SKB500 Combinations in Patients With Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2025-12-20","conditions":"Small Cell Lung Cancer","enrollment":80},{"nctId":"NCT05445908","phase":"PHASE2","title":"SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2022-08-17","conditions":"Triple-negative Breast Cancer and HR+/HER2- BC","enrollment":175},{"nctId":"NCT07179783","phase":"PHASE2","title":"Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2025-09-22","conditions":"Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Castration-Resistant, Prostate Adenocarcinoma With Neuroendocrine Differentiation","enrollment":28},{"nctId":"NCT07109284","phase":"PHASE2","title":"SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2025-09","conditions":"ER+HER2- Breast Cancer","enrollment":55},{"nctId":"NCT05294172","phase":"PHASE3","title":"KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2022-06-07","conditions":"Nasopharyngeal Carcinoma, Recurrent or Metastatic","enrollment":295},{"nctId":"NCT05351788","phase":"PHASE2","title":"SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.","status":"RECRUITING","sponsor":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","startDate":"2022-05-20","conditions":"Non-small Cell Lung Cancer","enrollment":110},{"nctId":"NCT03848286","phase":"PHASE2","title":"KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2019-03-06","conditions":"Nasopharyngeal Carcinoma, Recurrent or Metastatic","enrollment":153},{"nctId":"NCT03580564","phase":"PHASE2","title":"An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2018-08-01","conditions":"Classical Hodgkin Lymphoma","enrollment":109}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"KL-A167","genericName":"KL-A167","companyName":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","companyId":"sichuan-kelun-biotech-biopharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KL-A167 is a humanized monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}